SCHEMBL30945574

SCHEMBL30945574

Nc1ccc2ccc(-n3cncn3)nc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
MEN1 O00255 1/20 0.44
F2 P00734 1/20 0.44
CHRM2 P08172 1/20 0.44
HTR1A P08908 1/20 0.44
ADRA2A P08913 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
MAOA P21397 1/20 0.44
DRD1 P21728 1/20 0.44
ACHE P22303 1/20 0.44
PTGS1 P23219 1/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A4 P31645 1/20 0.44
OPRM1 P35372 1/20 0.44
DRD3 P35462 1/20 0.44
KDR P35968 1/20 0.44
HTT P42858 1/20 0.44
SLC6A3 Q01959 1/20 0.44
KMT2A Q03164 1/20 0.44
KCNH2 Q12809 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8669666 0.78 ALDH1A1 (0.44) LMNAHTR1ASLC6A4HTTKMT2A
SCHEMBL1163933 0.73 MAPT (0.45) LMNAMEN1HTTKMT2AKDM4E
SCHEMBL14908821 0.71 PIM1 (0.43) LMNAKCNH2KDM4EMAPTALDH1A1
SCHEMBL1061978 0.70 ADORA2A (0.38) LMNAMEN1KMT2AKDM4EMAPT
SCHEMBL31507714 0.70 ADORA2A (0.43) LMNAADORA3KDM4EALDH1A1HSD17B10
SCHEMBL28303005 0.69 CYP2A6 (0.47) LMNAMEN1HTTKMT2AKDM4E
SCHEMBL31556855 0.68 KDM4E (0.45) LMNAMEN1HTTKMT2AKDM4E
SCHEMBL21623963 0.68 KDM4E (0.45) LMNAMEN1HTTKMT2AKDM4E
SCHEMBL24313570 0.68 HRH3 (0.48) LMNAMEN1F2CHRM2HTR1A
SCHEMBL10568995 0.68 HRH3 (0.48) LMNAMEN1F2CHRM2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199613-A1 POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199613-A1 POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK1, KLK5 LMNA 893/4885MEN1 379/4885F2 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.